<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126516</url>
  </required_header>
  <id_info>
    <org_study_id>03-Ken-52</org_study_id>
    <nct_id>NCT00126516</nct_id>
  </id_info>
  <brief_title>Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline</brief_title>
  <official_title>Effects of Angiotensin II Receptor Blockers (ARB) and Angiotensin Converting Enzyme Inhibitors (ACEI) on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nara Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nara Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate whether or not angiotensin II receptor blockers
      (ARB) are more beneficial or equal to angiotensin converting enzyme inhibitors (ACEI) on
      development or progression of silent brain infarction and cognitive decline in Japanese
      patients with essential hypertension in the elderly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension plays a major role in the development of cardiovascular diseases. Treating
      hypertension has been associated with reduction in the risk of stroke and myocardial
      infarction. Angiotensin converting enzyme inhibitor (ACEI), ramipril, showed a 32 % in
      relative risk of reduction in the Heart Outcomes Prevention Evaluation (HOPE) trial.
      Angiotensin II receptor blocker (ARB), losartan, also showed a 25 % in relative risk of
      reduction in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE).

      Elderly people, especially hypertensive patients, with silent brain infarction have an
      increased risk of stroke and cognitive decline. However, no reports are seen on comparison of
      the effects of ARBs and ACEIs on progression of silent brain infarction and cognitive decline
      in patients with essential hypertension in the elderly.

      The researchers therefore longitudinally evaluate silent brain infarction using magnetic
      resonance imaging and cognitive decline by Mini-Mental State Examination twice at an interval
      of 2 years in patients with essential hypertension in the elderly who are received
      antihypertensive therapy by ARB or ACEI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatal and nonfatal stroke</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression of silent brain infarction or white matter lesion on magnetic resonance imaging</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatal and nonfatal acute coronary syndrome</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission for heart failure</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Brain Infarction</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiotensin II Receptor Antagonists group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiotensin-converting Enzyme Inhibitors group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II Receptor Antagonists</intervention_name>
    <description>any dosage, frequency, and duration</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin-converting Enzyme Inhibitors</intervention_name>
    <description>any dosage, frequency, and duration</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with essential hypertension (systolic blood pressure&gt;=140 mmHg and/or
             diastolic blood pressure&gt;=90, or treated with antihypertensive drugs)

          -  Patients with any finding of stroke, silent brain infarction, and white matter lesion
             on magnetic resonance imaging

        Exclusion Criteria:

          -  Secondary hypertension

          -  Atrial fibrillation

          -  History or signs of cerebral disorders other than cerebrovascular disease

          -  Malignant tumor

          -  Chronic renal failure

          -  Severe congestive heart failure

          -  Hyperkalemia

          -  Stenosis of bilateral renal artery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshihiko Saito, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Internal Medicine, Nara Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Department of Internal Medicine, Nara Medical University</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nara Medical University</investigator_affiliation>
    <investigator_full_name>Yoshihiko Saito</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>silent brain infarction</keyword>
  <keyword>cognitive decline</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

